Pharmaceutical News

RSS

Hi-Tech Pharmacal receives clearance from FDA to market Tropazone lotion

Hi-Tech Pharmacal Co., Inc. announced today that it received clearance from the FDA to market Tropazone™ lotion, a prescription dermatological product which will be promoted by Hi-Tech’s branded marketing subsidiary, ECR Pharmaceuticals Co., Inc. The product is indicated for the treatment of various dermatological conditions including atopic dermatitis, allergic contact dermatitis, and radiation dermatitis.

8 Jan 2010

Murad launches new line of Anti-Aging Acne products for adults struggling with acne

Murad, Inc. has announced the launch of a new line of Anti-Aging Acne products for adults struggling with acne. The new Anti-Aging Acne line is the first comprehensive approach designed to restore a smooth, youthful complexion by addressing acne breakouts while diminishing the appearance of fine lines and wrinkles.

8 Jan 2010

Kyowa Hakko Kirin receives exclusive rights to develop and commercialize bardoxolone methyl

Reata Pharmaceuticals, Inc. (Reata) and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) announced today that they have entered into a licensing agreement that provides Kyowa Hakko Kirin with the exclusive rights to develop and commercialize Reata’s lead compound, bardoxolone methyl (bardoxolone), in Japan and other selected Asian markets.

8 Jan 2010

Biovest International receives Orphan Drug Designation for its personalized lymphoma vaccine

Biovest International, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest’s personalized lymphoma vaccine. BiovaxID represents a new class of active immunotherapy and is one of the few select late-stage patient-specific cancer vaccines vying to be among the first to reach market.

8 Jan 2010

UCLA: Metformin can be used to treat patients with diabetes and advanced heart failure

A new study has shown that metformin, a drug often used in the treatment of diabetes mellitus, is safe for use in treating patients who have both diabetes and advanced heart failure.

7 Jan 2010

UAB issues updated guidelines for childhood and teen immunization schedule

The co-director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases is a member of the committee that this week issued updated guidelines for childhood and teen immunizations to include formal recommendations that children older than 6 months get the H1N1 influenza vaccine to guard against swine flu, and that combination vaccines are generally preferred over separate injections.

7 Jan 2010

Carolinas MED-1 to house a clinic for residents to get H1N1 Flu shots

Carolinas MED-1 - the first mobile hospital of its kind in the world - will be serving the people of Charlotte and Mecklenburg County when it is deployed this Saturday for an H1N1 vaccine clinic.

7 Jan 2010

Canada loans 5m doses of H1N1 vaccine to Mexico

Canadian Health Minister Leona Aglukkaq on Wednesday announced plans for the country to loan Mexico five million doses of the H1N1 (swine flu) vaccine, Agence France-Presse reports.

7 Jan 2010

FDA issues Fast Track Designation to Sopherion Therapeutics' Myocet

Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet(TM)) for first-line therapy of HER2 positive metastatic breast cancer.

7 Jan 2010

Sales figures for Abstral presented in a press release in Europe

Orexo AB announces today that its partner ProStrakan Group plc has presented its sales figures for Abstral in Europe in a press release. ProStrakan states that sales of Abstral underwent a strong development in 2009 and sales in the range of GBP 5 M – GBP 6 M were achieved for full-year.

7 Jan 2010

Ceragenix Pharmaceuticals and BioPro Pharmaceutical enter into agreement to commercialize EpiCeram

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the “Agreement”) with BioPro Pharmaceutical, Inc. (“BioPro”), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the “Territories”).

7 Jan 2010

New Sermo Event Report assesses physicians' perception of multiple sclerosis drugs

Sermo (http://www.sermo.com), the world's largest online physician's community, today announced a new Sermo Event(TM) Report assessing physician perception of FDA's "refuse to file" (RTF) letter on EMD Serono's Cladribine tablets and its potential impact, if any, on Novartis' oral MS agent in development; Fingolimod. Cladribine is expected to be one of the first oral agents to be approved for the treatment of relapsing and remitting multiple sclerosis.

7 Jan 2010

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy

Scientists in Massachusetts are reporting new evidence that certain high blood pressure drugs may be useful in preventing and treating diabetic retinopathy, the leading cause of vision loss in people with diabetes. The study, the largest to date on proteins in the retina, could lead to new ways to prevent or treat the sight-threatening disease, they say.

7 Jan 2010

Virginia elementary school children will receive their second dose of H1N1 vaccine

On Thursday, January 7, U.S. Department of Health and Human Services Secretary Kathleen Sebelius, Secretary of Education Arne Duncan and the U.S. Surgeon General Dr. Regina Benjamin will visit a school-based flu vaccination clinic at Carlin Springs Elementary in Arlington, Virginia, where local elementary schoolchildren will receive their second dose of the H1N1 vaccine.

7 Jan 2010

Rituximab treatment reduces patients' response to pneumonia vaccine

Researchers from Johns Hopkins University determined that immune responses to the tetanus vaccine were not changed when rituximab in combination with methotrexate (MTX) was compared with MTX alone in patients with rheumatoid arthritis (RA).

7 Jan 2010

Microbia creates carotenoids for food ingredient and nutritional supplement markets

Microbia, Inc., an emerging leader in the production of sustainable specialty ingredients and biomaterials, today announced that it has achieved an important milestone in creating its line of naturally derived carotenoids for the food ingredient and nutritional supplement markets.

7 Jan 2010

CEI releases new diabetes market forecast study

Since 2008, Cutting Edge Information has developed forecasting data for the diabetes treatment market. The new report -- "Diabetes Market Forecast to 2015" -- provides a deep analysis of the relevant clinical, commercial, and market trends affecting diabetes therapeutics today and their impact leading into the next decade. In addition to detailed drug, class, and company profiles, the study includes primary research findings generated from survey data and interviews with leading physicians and marketing executives.

7 Jan 2010

Drug companies still under great and growing pressure to bring more products to market

Although drug developers are improving R&D efficiency, in part by terminating more unpromising drugs earlier in development, their continued success will depend on how well they partner with other firms at specific points on the development spectrum, according to the Tufts Center for the Study of Drug Development.

7 Jan 2010

ProFibrix B.V. receives loan up to $7.4 million to develop its new hemostat Fibrocaps

ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that SenterNovem, an agency of the Dutch Ministry of Economic Affairs, has granted the company a loan under its new Innovation Credit scheme of potentially up to EUR 5 million to finance the further clinical development of its unique new hemostat Fibrocaps(TM).

7 Jan 2010

Teva Pharmaceutical Industries enters into two definitive agreements with AstraZeneca

Teva Pharmaceutical Industries Ltd. announced today that it has entered into two definitive agreements with AstraZeneca to settle patent litigation regarding Teva’s U.S. generic versions of AstraZeneca’s Prilosec® (omeprazole) and Nexium® (esomeprazole), including all claims for patent infringement and damages.

7 Jan 2010

Pharmaceutical News

Hi-Tech Pharmacal receives clearance from FDA to market Tropazone lotion

Murad launches new line of Anti-Aging Acne products for adults struggling with acne

Kyowa Hakko Kirin receives exclusive rights to develop and commercialize bardoxolone methyl

Biovest International receives Orphan Drug Designation for its personalized lymphoma vaccine

UCLA: Metformin can be used to treat patients with diabetes and advanced heart failure

UAB issues updated guidelines for childhood and teen immunization schedule

Carolinas MED-1 to house a clinic for residents to get H1N1 Flu shots

Canada loans 5m doses of H1N1 vaccine to Mexico

FDA issues Fast Track Designation to Sopherion Therapeutics' Myocet

Sales figures for Abstral presented in a press release in Europe

Ceragenix Pharmaceuticals and BioPro Pharmaceutical enter into agreement to commercialize EpiCeram

New Sermo Event Report assesses physicians' perception of multiple sclerosis drugs

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy

Virginia elementary school children will receive their second dose of H1N1 vaccine

Rituximab treatment reduces patients' response to pneumonia vaccine

Microbia creates carotenoids for food ingredient and nutritional supplement markets

CEI releases new diabetes market forecast study

Drug companies still under great and growing pressure to bring more products to market

ProFibrix B.V. receives loan up to $7.4 million to develop its new hemostat Fibrocaps

Teva Pharmaceutical Industries enters into two definitive agreements with AstraZeneca

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News